Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the Phase 3, randomised SELECT-COMPARE study
RMD Open 2024;10:e004007 doi: 10.1136/rmdopen-2023-004007
More RA patients on upadacitinib versus adalimumab achieved clinical remission, LDA, and DAS28 (CRP) <2.6. Radiographic progression was less with continuous upadacitinib versus continuous adalimumab. Upadacitinib showed similar safety to adalimumab, with higher incidences of HZ, lymphopenia, CPK elevation, hepatic disorder and nonmelanoma skin cancer.
Fleischmann, et al. compared upadacitinib and adalimumab over 5 years in RA patients with inadequate response to methotrexate. Patients were initially randomised 2:2:1 to upadacitinib 15mg QD, placebo, or adalimumab 40mg EOW, with some patients switching to upadacitinib or adalimumab if they did not show improvement in TJC and SJC. Patients who completed 48 weeks of treatment could enter an open-label LTE for up to 10 years.
Keywords:
